Preparation method and application of immunocytoma vaccine

Abstract

The invention discloses a preparation method of an immunocytoma vaccine and application of the immunocytoma vaccine in cancer therapy. The preparation method comprises the following steps: in a PBMC (peripheral blood mononuclear cell) culture medium for initial culture, adding a DC cell activation factor, and adding one or a plurality of tumor antigen proteins or long-chain polypeptides, wherein in such process, the tumor antigen is ingested by monocytes, decomposed and presented to the monocyte surface; on the basis of continuing culturing PBMC, adding a cell factor capable of promoting the monocyte to become the DC cell to be activated and mature, one or a plurality of toll-like receptor activating factors and one or a plurality of polypeptides capable of being combined with MHCI on the DC surface; and meanwhile, adding an anti-human CTLA-4 antibody, and coculturing to intercept the inhibiting action of the CTLA-4. The cells cultured by the method can increase tumor-antigen-specific T cells and obviously enhance and promote the capacity of the immunological cells for killing tumor cells, thereby enhancing the curative effect in clinical cancer therapy.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a preparation method and application of an immune cell tumor vaccine. Background technique [0002] Malignant tumors are the most serious diseases that endanger human health. Every year, about 3 million people in the country are diagnosed with new tumors, and more than 2 million people die of cancer. Although it can be treated by surgery, radiotherapy, and chemotherapy, most patients still die of tumor recurrence and metastasis. Therefore, how to remove the residual tiny tumor tissue or tumor cells is one of the problems to be solved in modern tumor immunology. Since the root cause of cancer is the uncontrolled growth of tumor cells escaping the monitoring of immune cells, improving the recognition and killing of tumor cells by the immune system will fundamentally remove the tumor. With the clinical application and promotion of new technologies, immunotherapy has graduall...

AI Technical Summary

Problems solved by technology

[0007] Due to the lack of control of immunosuppressive targets, the current clinically used DC tumor vaccines generally have low specificity and low efficacy after reinfusion

Images